Document is current

Any future updates will be listed below

Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer

Crossref DOI link: https://doi.org/10.1186/s13058-025-02203-6

Published Online: 2026-01-22

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark